Glenmark Pharmaceuticals Profit & Loss Annual
BSE: - | NSE: - | ISIN: - | Sector: -2,276.10 +10.85 (0.48%)Updated : 10 Jul 2026
| Fiscal Period | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Period End Date | Mar 26 | Mar 25 | Mar 24 | Mar 23 |
| Total Operating Expense | 15,249.66 | 11,829.19 | 12,100.63 | 11,283.26 |
| Other Net | 460.62 | 4.27 | 796.76 | 32.02 |
| Diluted Weighted Average Shares | 28.23 | 28.22 | 28.22 | 28.22 |
| Depreciation/ Amortization | 573.48 | 486.01 | 581.91 | 569.17 |
| Operating Income | 1,732.85 | 1,492.55 | -287.53 | 299.98 |
| Net Income | 1,361.85 | 1,047.10 | -1,501.67 | 297.25 |
| Income Availableto Com Excl Extra Ord | 1,361.85 | 1,047.10 | -1,899.00 | -169.72 |
| Other Operating Expenses Total | 4,084.78 | 754.10 | 697.26 | 597.03 |
| Net Income Before Taxes | 1,984.75 | 1,399.21 | 36.50 | 239.84 |
| Minority Interest | -0.10 | -0.05 | -68.15 | -80.16 |
| Net Income After Taxes | 1,361.95 | 1,047.14 | -1,830.85 | -89.56 |
| Income Availableto Com Incl Extra Ord | 1,361.85 | 1,047.10 | -1,501.67 | 297.25 |
| Costof Revenue Total | 4,747.46 | 4,888.74 | 5,003.04 | 4,698.35 |
| Gross Profit | 12,235.05 | 8,433.00 | 6,810.06 | 6,884.88 |
| Interest Inc( Exp) Net- Non- Op Total | -208.73 | -97.61 | -474.27 | -97.88 |
| Unusual Expense( Income) | 2,266.08 | 372.82 | 900.95 | 765.85 |
| Diluted Net Income | 1,361.85 | 1,047.10 | -1,501.67 | 297.25 |
| DPS- Common Stock Primary Issue | 5.00 | 2.50 | 2.50 | 2.50 |
| Provisionfor Income Taxes | 622.79 | 352.07 | 1,867.35 | 329.40 |
| period Type | - | - | - | - |
| Net Income Before Extra Items | 1,361.85 | 1,047.10 | -1,899.00 | -169.72 |
| Total Revenue | 16,982.51 | 13,321.74 | 11,813.10 | 11,583.24 |
| period Length | 12.00 | 12.00 | 12.00 | 12.00 |
| Revenue | 16,982.51 | 13,321.74 | 11,813.10 | 11,583.24 |
| Selling/ General/ Admin Expenses Total | 3,577.85 | 5,327.52 | 4,917.47 | 4,652.85 |
| Diluted Normalized EPS | 103.32 | 46.99 | -46.58 | 11.50 |
| Diluted EPS Excluding Extra Ord Items | 48.24 | 37.10 | -67.30 | -6.01 |
| Gain( Loss)on Saleof Assets | - | 0.00 | 1.53 | 5.73 |
| Total Extraordinary Items | - | 0.00 | 397.33 | 466.96 |
*All figures in crores except per share values
Glenmark Pharmaceuticals Quick Links
Glenmark Pharmaceuticals Dividend Glenmark Pharmaceuticals Bonus Glenmark Pharmaceuticals News Glenmark Pharmaceuticals AGM Glenmark Pharmaceuticals Rights Glenmark Pharmaceuticals Splits Glenmark Pharmaceuticals Board Meetings Glenmark Pharmaceuticals Key Metrics Glenmark Pharmaceuticals Shareholdings Glenmark Pharmaceuticals Balance Sheet Glenmark Pharmaceuticals Cashflow Glenmark Pharmaceuticals Q1 Results Glenmark Pharmaceuticals Q2 Results Glenmark Pharmaceuticals Q3 Results Glenmark Pharmaceuticals Q4 Results
Equity Quick Links
Top GainersTop LosersIndian IndicesBSE Active StocksNSE Active Stocks
1,845.00+45.70(2.54%)
1,456.05+31.80(2.23%)
1,072.00+21.95(2.09%)
289.70-2.55 (-0.87%)
1,916.05-14.45 (-0.75%)
✕
Wait for it…
Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.